Compare EWTX & WRBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EWTX | WRBY |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Ophthalmic Goods |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2021 | 2021 |
| Metric | EWTX | WRBY |
|---|---|---|
| Price | $43.29 | $27.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | ★ $39.00 | $27.10 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 105.88 |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $871,905,000.00 |
| Revenue This Year | N/A | $14.48 |
| Revenue Next Year | N/A | $16.41 |
| P/E Ratio | ★ N/A | $475.00 |
| Revenue Growth | N/A | ★ 13.04 |
| 52 Week Low | $13.69 | $14.96 |
| 52 Week High | $48.40 | $31.00 |
| Indicator | EWTX | WRBY |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 52.49 |
| Support Level | $37.50 | $24.24 |
| Resistance Level | $44.93 | $27.59 |
| Average True Range (ATR) | 2.15 | 1.71 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 65.09 | 40.67 |
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
Warby Parker Inc is a mission-driven, lifestyle brand that operates at the intersection of design, technology, healthcare, and social enterprise. The Company provides holistic vision care by offering eyewear, contacts, and eye care directly to consumers through its integrated, omnichannel platform. The company predominantly derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.